Clintons Refuse To Testify About Jeffrey Epstein; Comer To Begin Contempt Proceedings President Trump isn't the only one clamming up over Jeffrey Epstein - as Bill and Hillary Clinton are both refusing to testify in front of Congressional investigators over their relationship with the dead sex-trafficking pedophile, escalating a monthslong battle with House Oversight Committee Chairman Rep. James ...
Clintons Refuse To Testify About Jeffrey Epstein; Comer To Begin Contempt Proceedings President Trump isn't the only one clamming up over Jeffrey Epstein - as Bill and Hillary Clinton are both refusing to testify in front of Congressional investigators over their relationship with the dead sex-trafficking pedophile, escalating a monthslong battle with House Oversight Committee Chairman Rep. James Comer (R-KY). The Clintons were scheduled to testify this week - weeks after the Trump DOJ released volumes of 'Epstein Files' - which were highly redacted, yet featured Bill prominently. The former US president was scheduled to testify today (Jan. 13), and Hillary scheduled for tomorrow. Hours before the deadline, however, the Clintons made it clear in an 8-page letter that they have no intention of showing up - calling subpoenas issued by Comer "invalid and legally unenforceable," adding that they'll fight Comer as long as it takes. "They are obligated under the law to appear and we expect them to do so," and Oversight spokeswoman said last week. "If the Clintons do not appear for their depositions, the House Oversight Committee will initiate contempt of Congress proceedings." Which, they're now initiating for Bill (which Hillary to follow). Rep. James Comer (R-KY) Contempt of Congress is a misdemeanor that can result in a fine of up to $100,000 and up to a year in jail if pursued by the DOJ (so, nothing will happen and the Clintons know it). Comer subpoenaed the Clintons seeking information regarding their personal interactions with Epstein and Ghislaine Maxwell, including documented flights on Epstein's private jet. The Clintons said in their letter that they anticipated Mr. Comer would argue that the decision about whether to testify was not theirs to make. “But we have made it,” they wrote. “Now you have to make yours.” The Clintons had worked to beef up their legal team before Mr. Comer’s deadline. They brought on Ashley Callen, co-chair of the congressional investig...
Jan 13 (Reuters) - Microsoft on Tuesday unveiled an initiative to curb water usage at its U.S. data centers and limit the impact on the general population from any potential surge in power prices.
Jan 13 (Reuters) - Microsoft on Tuesday unveiled an initiative to curb water usage at its U.S. data centers and limit the impact on the general population from any potential surge in power prices.
UBS US Economist Abigail Watt sees upside risks to the inflation data and the big story for growth optimism this year is based on fiscal policy. She speaks to Bloomberg's Vonnie Quinn on 'Bloomberg Brief.' (Source: Bloomberg)
UBS US Economist Abigail Watt sees upside risks to the inflation data and the big story for growth optimism this year is based on fiscal policy. She speaks to Bloomberg's Vonnie Quinn on 'Bloomberg Brief.' (Source: Bloomberg)
Charles Myers, Chairman and Founder of Signum Global Advisors, discussed the limited impact of US sanctions on Iran due to China's ongoing purchase of approximately 90% of Iranian oil, effectively violating the sanctions. (Source: Bloomberg)
Charles Myers, Chairman and Founder of Signum Global Advisors, discussed the limited impact of US sanctions on Iran due to China's ongoing purchase of approximately 90% of Iranian oil, effectively violating the sanctions. (Source: Bloomberg)
An analyst upgraded the stock, a play on data center growth. The post Data Center Adjunct Touches Buy Point As Analyst Calls It A Buy appeared first on Investor's Business Daily .
An analyst upgraded the stock, a play on data center growth. The post Data Center Adjunct Touches Buy Point As Analyst Calls It A Buy appeared first on Investor's Business Daily .
JPMorgan Chase stock (JPM) is under some pressure in Tuesday's trading session after the major bank's earnings fell below fourth quarter estimates when accounting for the costs related to the Apple Card (AAPL) deal. HSBC Head of US Financials Research Saul Martinez discusses JPMorgan's earnings release and how it factors into his broader outlook for the major bank in 2026. To watch more expert ins...
JPMorgan Chase stock (JPM) is under some pressure in Tuesday's trading session after the major bank's earnings fell below fourth quarter estimates when accounting for the costs related to the Apple Card (AAPL) deal. HSBC Head of US Financials Research Saul Martinez discusses JPMorgan's earnings release and how it factors into his broader outlook for the major bank in 2026. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
In this article NVO LLY Follow your favorite stocks CREATE FREE ACCOUNT A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including N...
In this article NVO LLY Follow your favorite stocks CREATE FREE ACCOUNT A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The request, also covering Novo's older weight-loss drug Saxenda, follows a review by the U.S. Food and Drug Administration that found no evidence linking GLP-1 receptor agonists to an increased risk of suicidal thoughts or behavior. GLP-1 receptor agonists were originally developed to treat type 2 diabetes. They mimic a gut hormone that suppresses appetite, creating a feeling of fullness. The FDA had reached similar conclusion following a preliminary review in 2024, but had acknowledged at the time that it could not rule out a small risk because of limited data. The regulator said on Tuesday it had conducted further analyses of placebo-controlled clinical trials involving GLP-1 drugs, which did not show an increased risk of suicidal thoughts or behavior versus placebo, or of other psychiatric side effects such as anxiety, depression, irritability or psychosis. The review covered 91 trials involving 107,910 patients, including 60,338 who received a GLP-1 drug and 47,572 who received placebo, it said. Eli Lilly and Novo Nordisk did not immediately respond to Reuters' requests for comment. If you are having suicidal thoughts or are in distress, contact the Suicide & Crisis Lifeline at 988 for support and assistance from a trained counselor.
The S&P 500 Index ($SPX ) (SPY ) is down -0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.26%. March E-mini S&P futures (ESH26 ) are down -0.22%, and March E-mini Nasdaq futures (NQH26...
The S&P 500 Index ($SPX ) (SPY ) is down -0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.55%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.26%. March E-mini S&P futures (ESH26 ) are down -0.22%, and March E-mini Nasdaq futures (NQH26...
Sandisk hits 52-week high as AI infrastructure boom drives demand. BiCS8 technology and expanding hyperscaler partnerships position SNDK for sustained growth ahead.
Sandisk hits 52-week high as AI infrastructure boom drives demand. BiCS8 technology and expanding hyperscaler partnerships position SNDK for sustained growth ahead.